VIZIENT, INC. for VIZIENT INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Monitored provisions in H.R. 195 to repeal or delay tax provisions included in the Affordable Care Act including the medical device tax, tax assessment on health insurance plans and high-value "Cadillac" insurance plans. Hospital Tax Exemption and Community Benefit - Monitored congressional activities for potential changes to hospital community benefit requirements to maintain tax exemption.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHELSEA ARNONE | — |
| SHOSHANA KRILOW | — |
| STEVEN RIXEN | — |
Health Issues HCR
Group Purchasing - Conducted education and outreach efforts about the value hospital group purchasing organizations deliver the U.S. health care system. Drug Pricing - Supported the CREATES Act (S. 974), The Fair Access to Safe and Timely Generics Act (H.R. 2051), The Preserving Access to Affordable Generics (S.124), The Increasing Competition in Pharmaceuticals Act (S.297) and The Lower Drug Costs through Competition Act (H.R. 749). 340B Drug Discount program - Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored ongoing congressional reports and discussions around the program. Children's Health Insurance Program - Supported passage of legislation to extend the Children's Health Insurance Program. Supported provision in H.R. 195 to extend the program for 6 years, and provisions in H.R. 1892 that continued funding for four additional years. Supported efforts to stabilize ACA insurance markets - including continuing funding for cost-sharing reduction subsidies and other efforts to stabilize insurance markets. Supported inclusion of provision to repeal the Independent Payment Advisory Board (IPAB) in H.R. 1892. Opioid Abuse - Monitored legislation to enhance funding and treatment options to address opioid abuse and addiction issues. Engaged in support of taking steps to ease shortages of hospital-administered intravenous opioid solutions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHELSEA ARNONE | — |
| SHOSHANA KRILOW | — |
| STEVEN RIXEN | — |
Medicare/Medicaid MMM
340B Drug Discount Program - Opposed Medicare reimbursement reductions for hospitals eligible for the 340B drug discount program. Supported passage of H.R. 4392. Opposed H.R. 4710, S. 2312 and S.2453 and monitored congressional discussions around the program. Medicare Extenders - Supported extension of Medicare programs that support low-volume and Medicare-dependent hospitals included in H.R.1892. Medicaid Disproportionate Share Hospital (DSH) Payments - Supported delay of implementation of Medicaid DSH payment cuts included in H.R. 1892. Children's Hospital GME Support Reauthorization Act (H.R.5385, S.2597) - Endorsed passage of legislation to reauthorize the Children's Hospital GME program. Supported change to home infusion payments for Part B DME infusion drugs and infusion services payments included in H.R. 1892.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHELSEA ARNONE | — |
| SHOSHANA KRILOW | — |
| STEVEN RIXEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.